Authors Francesca Patarnello Vice-President Market Access & Government Affairs, AstraZeneca Italia, Milano - Italy DOI: https://doi.org/10.33393/grhta.2024.3025 Keywords: Early Access, Health Technology Assessment (HTA), Pricing and Reimbursement, Unmet need Abstract

Within the European evolutionary framework concerning citizens’ health, the focus shifts to the new HTA regulation, set to alter processes and influence decision-making at the individual country level regarding reimbursement and pricing. The ambitious goal of achieving faster and more uniform access will significantly reshape the evaluative model stabilized over the years, characterized by the creation of different rules and processes among member states and diverse output timelines across the countries.

The imminent adoption of a more collaborative process necessitates member countries and companies to address several steps to ensure a smooth transition without penalizing the unique aspects of individual countries or impeding real access. Italy, actively participating in European preparatory activities with AIFA, faces challenges in adapting its formal process due to AIFA’s ongoing reform since November 2022, which is not yet materialized.

National-level companies heavily depend on leadership and involvement rules from their HTA agencies, with the risk that agencies with more established engagement models with external stakeholders may present themselves on January 12, 2025, the start date of the new process for oncological and ATMP drugs, better prepared and may excel in designing scoping meetings and in formulating PICO.

Therefore, the activation of a country culture of HTA and a robust and extended “readiness” phase involving all stakeholders are desirable, along with the establishment of collaboration networks with universities and scientific societies to make valuable knowledge and qualified resources more readily available, crucial element for the delicate transition from the old to the new evaluative system.

Downloads

Download data is not yet available.

References How to Cite

Patarnello, F. (2024). HTA regulation: how is Italy moving?. Global and Regional Health Technology Assessment, 11(1), 51–54. https://doi.org/10.33393/grhta.2024.3025

Issue Section

Point of View

Categories License

Copyright (c) 2024 The authors

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors contributing to Global & Regional Health Technology Assessment agree to publish their articles under the CC-BY-NC 4.0 license, which allows third parties to re-use the work without permission as long as the work is properly referenced and the use is non-commercial.

 

Received 2024-01-25
Accepted 2024-02-05
Published 2024-03-05